Faupel R P, Gotzen R
Med Klin. 1979 Jun 8;74(23):929-34.
In 23 patients with essential hypertension of stage I and II according to the WHO, the effects of a fixed combination of a beta-receptor-blocker plus saluretic composed of 20 mg of metipranolol (Disorat 20) and 2.5 mg of butizid (Saltucin) = Torrat on blood pressure and important metabolic parameters (glucose, glucose tolerance, cholesterol, triglyceride, uric acid, plasma potassium and whole body potassium) were tested over a 6-month treatment period.
blood pressure and pulse rate were significantly reduced; bradycardia (pulse rate less than 60/min) was not observed. The metabolic parameters showed no significant changes during the 6-month treatment period. In no case did the therapy have to be discontinued because of undesirable effects. The investigations show that the combination has a good antihypertensive effect with few side-effects and that it has no influence on important metabolic parameters during long-term therapy.
根据世界卫生组织标准,对23例I期和II期原发性高血压患者,测试了由20毫克美替洛尔(双氯心安20)和2.5毫克布噻嗪(速尿心定)组成的β受体阻滞剂加利尿剂的固定复方制剂(托拉特)在6个月治疗期内对血压和重要代谢参数(葡萄糖、葡萄糖耐量、胆固醇、甘油三酯、尿酸、血钾和全身钾)的影响。
血压和脉搏率显著降低;未观察到心动过缓(脉搏率低于60次/分钟)。在6个月治疗期内,代谢参数无显著变化。在任何情况下,治疗均未因不良反应而中断。研究表明,该复方制剂具有良好的降压效果,副作用少,且在长期治疗中对重要代谢参数无影响。